{"commentary":{"count":156,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":84,"podcast":40,"youtube":31,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04102098\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"IMbrave050","nct_id":"NCT04102098","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=imbrave050-nct04102098. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"IMbrave050","arms":[{"description":"Participants will receive Atezolizumab + Bevacizumab until disease recurrence or unacceptable toxicity.","label":"Arm A (atezolizumab plus bevacizumab)","type":"EXPERIMENTAL"},{"description":"Active surveillance of participants.","label":"Arm B (active surveillance)","type":"NO_INTERVENTION"}],"collaborators":[],"completion_date":{"date":"2026-05-15","type":"ACTUAL"},"conditions":["Carcinoma, Hepatocellular"],"enrollment":{"count":668,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","type":"DRUG"},{"name":"Bevacizumab","type":"DRUG"}],"last_update":"2026-06-18","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-10-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Recurrence-Free Survival (RFS), as Determined by IRF","timeFrame":"Baseline up to approximately 33 months"}],"references":[{"citation":"Yopp A, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Cha E, Hack SP, Lian Q, Spahn J, Wu C, Qin S, Chow PK. Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. J Hepatol. 2026 Jun;84(6):1102-1111. doi: 10.1016/j.jhep.2026.01.006. Epub 2026 Jan 22.","pmid":"41580093","type":"DERIVED"},{"citation":"Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20.","pmid":"37871608","type":"DERIVED"},{"citation":"Hack SP, Spahn J, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol. 2020 May;16(15):975-989. doi: 10.2217/fon-2020-0162. Epub 2020 Apr 30.","pmid":"32352320","type":"DERIVED"}],"start_date":{"date":"2019-12-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation","url":"https://clinicaltrials.gov/study/NCT04102098"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/imbrave050-nct04102098"}